Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Did you take more than 400 MG of Bextra a day?

Have any of the following side effects occurred? (Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bextra Lawsuit

Bextra Side Effects Lawsuits | Side Effects: Stevens Johnson Syndrome, Heart Attack, Strokes, Cardiovascular Injuries

Bextra Side Effects May Link To False Claims Lawsuits

Bextra Side Effects

Bextra | Lawsuits, Lawyers |Side Effects: Stevens Johnson Syndrome, Heart Attack, Strokes, Cardiovascular Injuries

On April 7, 2005, the FDA and European regulators formally asked Pfizer to suspend sales of Bextra in the United States and Europe. As a result, Pfizer announced it would halt sales of the drug in the United States and the European Union countries immediately. The FDA stated that the risks posed by Bextra outweigh its benefits. These risks include a high rate of heart attacks, strokes, other cardiovascular injuries and Stevens Johnson Syndrome.

FDA advisory committee hearings held in February 2005 examined whether Celebrex and Bextra offered enough benefits to stay on the market, if they needed stronger warnings and what further research was needed. The advisers met from February 16, 2005 through February 18, 2005 and ultimately voted to keep Bextra on the market. The New York Times reported that 10 of the 32 government drug advisers who voted to keep Bextra and the other COX-2 drugs on the market have consulted for pharmaceutical manufacturers. If these 10 advisers had not cast their votes, the committee would have voted 12 to 8 that Bextra should be withdrawn.

Bextra (generic name: valdecoxib), a Cox-2 Inhibitor drug, is in the same drug family as Vioxx, Celebrex and Naproxen. People prescribed Bextra have experienced a higher number of heart attacks, strokes and other cardiovascular problems. Bextra is prescribed for the treatment of adult rheumatoid arthritis, and the pain associated with menstrual cramping.

Bextra has also been linked to Stevens Johnson Syndrome and other skin hypersensitivity disorders

Stevens Johnson Syndrome is an extreme allergic reaction to chemicals. Common causes are the drugs including Arava (leflunomide), painkillers, and sulfa antibiotics. Bextra has now been linked to this potentially life threatening syndrome. Symptoms of Stevens Johnson Syndrome are blistering, fever, cough, malaise, swelling and lesions of gums, tongue, or lips, excessive tearing or "stickiness" of eyes, sores in the genital tract causing painful urination, skin rash, difficulty breathing. Patients who have severe allergies to antibiotics should not use Bextra.

Merck voluntarily withdrew Vioxx in September after a study showed the drug doubled the risk of heart attack and stroke in patients who took it for at least 18 months. Following the Vioxx recall, questions arose about the similar pain pills from Pfizer, Celebrex and Bextra, as well as non-prescription drugs such as Naproxen (Aleve). All pain drugs in the class known as Cox-2 Inhibitors increase the risk of heart attacks and strokes, a top scientist told a US regulatory panel. Dr. Garret Fitzgerald, a cox-2 expert and researcher at the University of Pennsylvania, said the body reacts in the same way to drugs including Merck's Vioxx and Pfizer's Celebrex and Bextra. Dr. Fitzgerald said the drugs create an imbalance in the body's cardiovascular system that leads to an increased risk of heart attacks and strokes.

Need Legal Help Regarding Bextra Side Effects?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



Bextra LawsuitRSS Feed

Medication Increases the Risk of Recurrent Falls

Apr 18, 2017
Researchers have found that low-extremity osteoarthritis (OA) patients who take opioids or antidepressants have an increased risk of repeated falls. Compared to individuals not taking any analgesics (painkillers), knee OA patients who used opioids had a 22 percent increased risk of recurrent falls, reports MedPage Today. Research on Recurrent Falls Wei-Hsuan Lo-Ciganic, PhD, of the University of Arizona College of Pharmacy, and colleagues reported in Osteoarthritis and Cartilage, this is...

Doctor Accused of Falsifying Drug Studies Pleads Guilty

Feb 23, 2010 | Parker Waichman LLP
Dr. Scott S. Reuben, former chief of acute pain at the Bay State Hospital in Springfield, Massachusetts, has pleaded guilty to one count of health care fraud. As we’ve reported previously, Reuben was charged in federal court last month with falsifying studies involving the post-surgical benefits of drugs like Vioxx, Bextra, Celebrex, Effexor and Lyrica. According to the Associated Press, federal prosecutors in Massachusetts had alleged that Reuben sought and received research grants from...

Pfizer's Illegal Promotion of Bextra and Other Drugs Results in Record Settlement, Guilty Plea

Sep 3, 2009 | Parker Waichman LLP
Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Company Inc., have agreed to pay a record-setting $2.3 billion to settle claims arising from the  illegal marketing  of some drugs.  According to a U.S. Department of Justice press release,  Pharmacia & Upjohn Company has also agreed to plead guilty to a felony violation regarding off-label promotions of the painkiller Bextra. Bextra was withdrawn from the market in 2005.As we've reported previously, doctors may...

Pfizer to Pay Big Fine Over Bextra Promotion

Jan 29, 2009 | Parker Waichman LLP
Drug maker Pfizer, Inc. led the news with two announcements this week:  It took a record-breaking hit of $2.3 billion over investigations into its improper marketing of the painkiller Bextra and other medications and it is acquiring its rival, Wyeth, for $68 billion, reported Bloomberg News.  Pfizer recalled Bextra in 2005 over a rare skin condition and at the urging of the U.S. Food and Drug Administration (FDA).Pfizer reached the $2.3 billion agreement with the Massachusetts U.S....

Arizona Bextra Lawsuit Charges Pfizer with Deceptive Marketing

Nov 19, 2008 | Parker Waichman LLP
In 2005, the U.S. Food and Drug Administration (FDA) and European regulators formally asked Pfizer, Inc. to suspend sales of Bextra in the United States and Europe.  As a result, Pfizer announced it would halt sales of the drug in the United States and the European Union countries immediately. The FDA stated that the risks—a high rate of heart attacks, strokes, other cardiovascular injuries, and Stevens Johnson Syndrome—posed by Bextra outweighed its benefits.  Now, the...

More Bextra Lawsuit News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo